Fingerprint
Dive into the research topics of 'Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression
Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), and GLSG (Gunma Liver Study Group)
Research output: Contribution to journal › Article › peer-review
18
Scopus
citations